Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

OptimizeRx (OPRX) EBITDA Margin (2016 - 2025)

OptimizeRx (OPRX) has disclosed EBITDA Margin for 16 consecutive years, with 26.58% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 1533.0% to 26.58% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 10.69% through Dec 2025, up 2556.0% year-over-year, with the annual reading at 10.78% for FY2025, 2554.0% up from the prior year.
  • EBITDA Margin hit 26.58% in Q4 2025 for OptimizeRx, up from 7.86% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 26.58% in Q4 2025 to a low of 54.32% in Q1 2023.
  • Historically, EBITDA Margin has averaged 13.64% across 5 years, with a median of 14.78% in 2024.
  • Biggest five-year swings in EBITDA Margin: crashed -3404bps in 2023 and later soared 4968bps in 2024.
  • Year by year, EBITDA Margin stood at 3.06% in 2021, then crashed by -244bps to 4.4% in 2022, then crashed by -774bps to 38.43% in 2023, then soared by 129bps to 11.25% in 2024, then soared by 136bps to 26.58% in 2025.
  • Business Quant data shows EBITDA Margin for OPRX at 26.58% in Q4 2025, 7.86% in Q3 2025, and 10.92% in Q2 2025.